[Clinical importance of determining steroid hormone receptors in endometrial adenocarcinomas].
Estradiol receptor (ER) and progesterone receptor (PR) levels were measured in 216 endometrial adenocarcinomas. Tumors containing more than 10 fmol/mg protein (for ER) and 20 fmol/mg (for PR) were considered receptor-positive. Tumors were both ER- and PR-positive in 75%. In stage I and II tumors, ER and PR levels were significantly higher than in stages III and IV. A similar relationship was established for minor (not deeper than 0.5 cm) and considerable involvement (deeper than 0.5 cm). There was an inverse correlation between ER and PR levels and ER- and PR-positive tumors incidence, on the one hand, and anaplasia, on the other. Adjuvant progestin therapy proved ineffective in tumors with a PR level under 100 mol/mg protein.
D000230:Adenocarcinoma / Q000032:analysis* / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D004958:Estradiol / Q000032:analysis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011374:Progesterone / Q000032:analysis*; D045167:Progesterone Congeners / Q000627:therapeutic use; D011959:Receptors, Estradiol / Q000032:analysis*; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012189:Retrospective Studies; D014594:Uterine Neoplasms / Q000032:analysis* / Q000188:drug therapy / Q000473:pathology
D045167:Progesterone Congeners; D011959:Receptors, Estradiol; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D011374:Progesterone; D004958:Estradiol
Klinicheskoe znachenie opredeleniia retseptorov steroidnykh gormonov v adenokartsinomakh éndometriia.